- Home
- PCM vs TLPH Comparison
PCM vs TLPH Comparison
Compare PCM & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | TLPH |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 70.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | PCM | TLPH |
|---|---|---|
| Price | $5.66 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 265.5K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.48 | $0.40 |
| 52 Week High | $6.76 | $1.57 |
Technical Indicators
Market Signals| Indicator | PCM | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 42.79 |
| Support Level | $5.65 | $0.74 |
| Resistance Level | $5.83 | $1.45 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 40.00 | 23.08 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.